Announcement Summary

Entity name

PHARMX TECHNOLOGIES LIMITED

Applicable security for the return of capital

PHX - ORDINARY FULLY PAID

Announcement Type

New announcement

Date of this announcement

22/11/2023

Return of Capital amount per security

AUD 0.00750000

Trading in the re-organised +securities on an "ex return of capital" basis commences

28/11/2023

Record Date

29/11/2023

Payment Date

4/12/2023

Additional Information

n/a

Refer to below for full details of the announcement

Announcement Details	;
----------------------	---

Part 1 - Entity and announcement details

1.1 Name of +Entity

PHARMX TECHNOLOGIES LIMITED

1.2 Registered Number Type

ABN

1.3 ASX issuer code

PHX

1.4 The announcement is

☑ New announcement

1.5 Date of this announcement

22/11/2023

1.6 ASX +Security Code

PHX

ASX +Security Description

ORDINARY FULLY PAID

Part 2 - Cash return of capital approval requirements and dates

2.1 Are any of the below approvals required for the cash return of capital before business day 0 of the timetable?

Registration Number

25000091305

- Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity required to be given/met before business day 0 of the timetable for the cash return of capital.

☑ No

2.2 Is the cash return of capital a selective reduction of capital

☑ No



Part 3 - Cash return of capital timetable and details

3.1 +Record date

29/11/2023

3.1a Effective date of the cash return of capital

24/11/2023

3.2 Does the +entity have quoted options on issue?

€ No

- 3.2a Last day for trading in "cum return of capital" +securities. If the entity has quoted options, last day for trading in pre-return of capital quoted options
- 3.3 Trading in the re-organised +securities on an "ex return of capital" basis commences. If the entity has quoted options and ASX agrees, trading in the quoted options commences on a +deferred settlement basis.

28/11/2023

3.4 +Record Date

29/11/2023

- 3.4a If the entity has quoted options, first day for the +entity to send holding statements to +security holders notifying them of the change in exercise price for the quoted options they hold.
- 3.5 Payment date for cash return of capital. If applicable and the +entity has quoted options, +deferred settlement market in options ends. Last day for entity to send holding statements to +security holders notifying them of the change in exercise price for the quoted options they hold and to notify ASX that this has occurred.

4/12/2023

- 3.5a If the +entity has quoted options, trading in the options starts on a normal T+2 basis
- 3.5b If the +entity has quoted options, first settlement of trades conducted on a +deferred settlement basis and on a normal T+2 basis
- 3.6 Currency in which the cash return of capital is made ("primary currency")

AUD - Australian Dollar

3.7 Cash return of capital amount per +security

AUD 0.00750000

Part 4 - Changes to option pricing as a result of the cash return of capital

4.1 Will the cash return of capital affect the exercise price of any +entity-issued options?
⊗ No

Part 5 - Further information

5.1 Has the +entity applied for an ATO class ruling relating to this cash return of capital?
⊗ Yes

5.1a Please provide further information on the ATO ruling

The Company will seek a class ruling from the Australian Taxation Office (ATO) for confirmation on certain Australian tax implications for shareholders receiving the capital return. Specifically the class ruling application seeks ATO confirmation as to: (i) the treatment of the Capital Return received by Shareholders as a capital payment and not a dividend; (ii) the associated Australian Capital Gains Tax (CGT) implications for Shareholders receiving the capital return; and (iii) whether the ATO will seek to apply any of the relevant integrity measures to the Capital Return. The final class ruling will be received from the ATO after the AGM. Once the class ruling is finalised by the ATO, it will be published on the ATO's website and the Company's website.

5.2 Source of funds for cash return of capital

A portion of net sale proceeds from sale of all of shares of Corum Health Pty Ltd and Amfac Pty Ltd to Jonas Software AUS Pty Ltd on 29 September 2023 and a portion of the Company's corporate cash reserves that will be surplus to the needs of the Company.

5.3 Further information relating to this cash return of ca
--

n/a

5.4 Additional information for inclusion in the Announcement Summary

n/a